On the move: the latest East Midlands hires

Andrew Lawday

Derbyshire-based managed service provider IDT has appointed Andrew Lawday as its new first line support engineer.

Lawday said: “Since starting at IDT, I have not once felt unwelcome. Everyone made great efforts to ensure I was given the resources needed to learn the ropes. I’ve always felt like my opinion was valid and given responsibilities based on my ability, which is important to me given the circumstances under which I came to apply for the job. Luke, James and Lawrie all showed that they cared more about my drive, passion for the field, and my fit within the IDT family than the limited qualifications I possessed. These qualities have led to the growth of a happy, healthy, effective team.”

IDT managing director Luke Draper said: “We’re delighted to have Andrew on board. He joins IDT at a very exciting time for the company as more and more clients choose us for a people-led services.

“Andrew has settled in seamlessly and we’re already receiving excellent feedback from customers on the first-class service he provides to them. We’re really looking forward to watching Andrew grow into the role over the coming months and years.”

Lawday added: “IDT really have a unique relationship with all their customers, which was plain to see from my very first interactions with them. On my first site visit, I got to see first-hand what professional, yet friendly service really looks like. Despite the brevity of my time spent with IDT, I already know that this is the kind of company I can really feel part of and fully get behind.”

Elsewhere, Nottingham-based CRO Cellomatics Biosciences has appointed Professor David Lambert, FRCA and FFPMRCA as chief scientific officer.

Founded in 2015, Cellomatics specialises in a range of therapeutic areas including oncology, immuno-oncology, immunology, inflammation and respiratory.

Professor Lambert will retain a part-time contract with the University of Leicester as Professor of Anaesthetic Pharmacology and deputy head of the Cardiovascular Sciences Department. He is a Fellow of the British Pharmacological Society and brings 35 years of research experience to Cellomatics.

Lambert, who previously worked with the company as a scientific advisor, said: “I have always toyed with the idea of working in industry but have never had a big enough draw before. That all changed when I began working with Cellomatics – a fast-growing CRO with exciting growth potential. I’m looking forward to applying my expertise to support the company’s continued growth and make a real difference, both within the team and for clients.”

Dr Shailendra Singh, CEO at Cellomatics, said: “David is a highly valued and trusted advisor to Cellomatics, and we are delighted to welcome him to the team. His extensive pharmacology expertise, knowledge and insights will be integral to our future growth as we set out to develop a pharmacology specialism in-house for the benefit of our clients.”